Histone deacetylase 1 interacts with HIV-1 Integrase and modulates viral replication.


Journal

Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645

Informations de publication

Date de publication:
19 11 2019
Historique:
received: 22 07 2019
accepted: 05 11 2019
entrez: 21 11 2019
pubmed: 21 11 2019
medline: 29 4 2020
Statut: epublish

Résumé

HIV-1 hijacks the cellular machinery for its own replication through protein-protein interactions between viral and host cell factors. One strategy against HIV-1 infection is thus to target these key protein complexes. As the integration of reverse transcribed viral cDNA into a host cell chromosome is an essential step in the HIV-1 life cycle, catalyzed by the viral integrase and other important host factors, we aimed at identifying new integrase binding partners through a novel approach. A LTR-derived biotinylated DNA fragment complexed with the integrase on magnetic beads was incubated with extracts from integrase-expressing 293 T cells. Liquid chromatography-mass spectrometry/mass spectrometry and co-immunoprecipitation/pull-down experiments were used for the identification of binding partners. Transfections of histone deacetylase 1 (HDAC1) expression vectors and/or specific siRNA were conducted in HeLa-CD4 and 293 T cells followed by infection with fully infectious NL4-3 and luciferase-expressing pseudotyped viruses or by proviral DNA transfection. Fully infectious and pseudotyped viruses produced from HDAC1-silenced 293 T cells were tested for their infectivity toward HeLa-CD4 cells, T cell lines and primary CD4+ T cells. Late RT species and integrated viral DNA were quantified by qPCR and infectivity was measured by luciferase activity and p24 ELISA assay. Results were analyzed by the Student's t-test. Using our integrase-LTR bait approach, we successfully identified new potential integrase-binding partners, including HDAC1. We further confirmed that HDAC1 interacted with the HIV-1 integrase in co-immunoprecipitation and pull-down experiments. HDAC1 knockdown in infected HeLa cells was shown to interfere with an early preintegration step of the HIV-1 replication cycle, which possibly involves reverse transcription. We also observed that, while HDAC1 overexpression inhibited HIV-1 expression after integration, HDAC1 knockdown had no effect on this step. In virus producer cells, HDAC1 knockdown had a limited impact on virus infectivity in either cell lines or primary CD4+ T cells. Our results show that HDAC1 interacts with the HIV-1 integrase and affects virus replication before and after integration. Overall, HDAC1 appears to facilitate HIV-1 replication with a major effect on a preintegration step, which likely occurs at the reverse transcription step.

Sections du résumé

BACKGROUND
HIV-1 hijacks the cellular machinery for its own replication through protein-protein interactions between viral and host cell factors. One strategy against HIV-1 infection is thus to target these key protein complexes. As the integration of reverse transcribed viral cDNA into a host cell chromosome is an essential step in the HIV-1 life cycle, catalyzed by the viral integrase and other important host factors, we aimed at identifying new integrase binding partners through a novel approach.
METHODS
A LTR-derived biotinylated DNA fragment complexed with the integrase on magnetic beads was incubated with extracts from integrase-expressing 293 T cells. Liquid chromatography-mass spectrometry/mass spectrometry and co-immunoprecipitation/pull-down experiments were used for the identification of binding partners. Transfections of histone deacetylase 1 (HDAC1) expression vectors and/or specific siRNA were conducted in HeLa-CD4 and 293 T cells followed by infection with fully infectious NL4-3 and luciferase-expressing pseudotyped viruses or by proviral DNA transfection. Fully infectious and pseudotyped viruses produced from HDAC1-silenced 293 T cells were tested for their infectivity toward HeLa-CD4 cells, T cell lines and primary CD4+ T cells. Late RT species and integrated viral DNA were quantified by qPCR and infectivity was measured by luciferase activity and p24 ELISA assay. Results were analyzed by the Student's t-test.
RESULTS
Using our integrase-LTR bait approach, we successfully identified new potential integrase-binding partners, including HDAC1. We further confirmed that HDAC1 interacted with the HIV-1 integrase in co-immunoprecipitation and pull-down experiments. HDAC1 knockdown in infected HeLa cells was shown to interfere with an early preintegration step of the HIV-1 replication cycle, which possibly involves reverse transcription. We also observed that, while HDAC1 overexpression inhibited HIV-1 expression after integration, HDAC1 knockdown had no effect on this step. In virus producer cells, HDAC1 knockdown had a limited impact on virus infectivity in either cell lines or primary CD4+ T cells.
CONCLUSIONS
Our results show that HDAC1 interacts with the HIV-1 integrase and affects virus replication before and after integration. Overall, HDAC1 appears to facilitate HIV-1 replication with a major effect on a preintegration step, which likely occurs at the reverse transcription step.

Identifiants

pubmed: 31744547
doi: 10.1186/s12985-019-1249-y
pii: 10.1186/s12985-019-1249-y
pmc: PMC6862858
doi:

Substances chimiques

HIV Integrase EC 2.7.7.-
HDAC1 protein, human EC 3.5.1.98
Histone Deacetylase 1 EC 3.5.1.98
p31 integrase protein, Human immunodeficiency virus 1 YY6481J2FF

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

138

Références

J Biol Chem. 2012 Nov 30;287(49):40858-66
pubmed: 23043109
EMBO J. 2007 Jan 24;26(2):412-23
pubmed: 17245431
Expert Rev Mol Med. 2007 Feb 26;9(6):1-19
pubmed: 17320002
J Mol Biol. 2011 Jul 29;410(5):847-62
pubmed: 21763491
J Virol. 1997 Mar;71(3):1922-30
pubmed: 9032323
J Virol. 2006 Jun;80(12):5670-7
pubmed: 16731905
J Virol. 2007 Sep;81(18):10037-46
pubmed: 17626089
Retrovirology. 2009 Dec 04;6:111
pubmed: 19961595
Subcell Biochem. 2007;41:193-212
pubmed: 17484129
J Virol. 2014 Sep;88(18):10803-12
pubmed: 25008921
Nat Rev Drug Discov. 2006 Sep;5(9):769-84
pubmed: 16955068
J Biol Chem. 2009 Mar 20;284(12):7931-9
pubmed: 19150986
J Virol. 1995 Nov;69(11):6705-11
pubmed: 7474080
Chembiochem. 2010 Jul 26;11(11):1501-4
pubmed: 20578118
FASEB J. 2000 Jul;14(10):1389-99
pubmed: 10877832
PLoS Pathog. 2009 Jun;5(6):e1000463
pubmed: 19503603
Retrovirology. 2010 Mar 12;7:18
pubmed: 20226045
J Biol Chem. 2006 May 5;281(18):12495-505
pubmed: 16540471
J Virol. 1995 Nov;69(11):6687-96
pubmed: 7474078
J Virol. 2016 Dec 16;91(1):
pubmed: 27795445
J Biol Chem. 2015 Jun 26;290(26):16077-87
pubmed: 25918162
Gene. 1993 Dec 27;137(1):139-43
pubmed: 7506688
Mol Cell. 2001 Jun;7(6):1245-54
pubmed: 11430827
J Biol Chem. 2003 Jan 3;278(1):372-81
pubmed: 12407101
J Virol. 2000 Aug;74(15):6790-9
pubmed: 10888618
J Virol. 2002 Feb;76(3):1004-14
pubmed: 11773376
Oncogene. 2007 Aug 13;26(37):5310-8
pubmed: 17694074
J Biol Chem. 2005 Aug 12;280(32):29334-9
pubmed: 15958388
J Virol. 1996 Mar;70(3):1580-7
pubmed: 8627677
J Virol. 2007 Mar;81(6):3012-7
pubmed: 17182677
J Virol. 1986 Aug;59(2):284-91
pubmed: 3016298
Virology. 2000 Aug 1;273(2):307-15
pubmed: 10915601
J Biol Chem. 2009 Dec 11;284(50):34901-10
pubmed: 19822520
Gene Ther. 1999 May;6(5):715-28
pubmed: 10505094
Antivir Chem Chemother. 2014 Jan 29;23(4):145-9
pubmed: 24318952
J Virol. 2007 Oct;81(20):10914-23
pubmed: 17670825
J Virol. 2011 May;85(10):4654-66
pubmed: 21367893
J Virol. 2005 Aug;79(16):10356-68
pubmed: 16051828
J Virol. 1992 Apr;66(4):2232-9
pubmed: 1548759
J Virol. 1999 Mar;73(3):2126-35
pubmed: 9971795
Nature. 2012 Jul 25;487(7408):482-5
pubmed: 22837004
J Virol. 1995 May;69(5):2729-36
pubmed: 7535863
AIDS Res Hum Retroviruses. 2009 Feb;25(2):207-12
pubmed: 19239360
AIDS. 2004 May 21;18(8):1101-8
pubmed: 15166525
EMBO J. 2006 Jan 11;25(1):139-49
pubmed: 16319923
Protein Sci. 1994 Jun;3(6):888-97
pubmed: 8069220
J Virol. 2004 May;78(10):5056-67
pubmed: 15113887
Cell Host Microbe. 2011 Jun 16;9(6):484-95
pubmed: 21669397
PLoS One. 2014 Aug 19;9(8):e102684
pubmed: 25136952
Virus Genes. 2003 Oct;27(2):177-88
pubmed: 14501196
J Virol. 2004 Nov;78(21):11563-73
pubmed: 15479797
J Virol. 2004 May;78(10):5045-55
pubmed: 15113886
EMBO J. 2007 Dec 12;26(24):4985-95
pubmed: 18007589
J Biol Chem. 2006 Aug 11;281(32):22736-43
pubmed: 16772295
J Virol. 1997 Feb;71(2):1025-35
pubmed: 8995622
EMBO J. 2005 Sep 7;24(17):3070-81
pubmed: 16096645
Curr Genet. 1997 Aug;32(2):157-62
pubmed: 9294265
J Virol. 2010 May;84(10):5181-90
pubmed: 20219923
J Virol. 2009 May;83(10):4749-56
pubmed: 19279091
PLoS One. 2009 Nov 13;4(11):e7825
pubmed: 19915660

Auteurs

Fadila Larguet (F)

Département des sciences biologiques, and Centre de recherche BioMed, Université du Québec à Montréal, Montréal, QC, Canada.

Clément Caté (C)

Département des sciences biologiques, and Centre de recherche BioMed, Université du Québec à Montréal, Montréal, QC, Canada.

Benoit Barbeau (B)

Département des sciences biologiques, and Centre de recherche BioMed, Université du Québec à Montréal, Montréal, QC, Canada.

Eric Rassart (E)

Département des sciences biologiques, and Centre de recherche BioMed, Université du Québec à Montréal, Montréal, QC, Canada. rassart.eric@uqam.ca.

Elsy Edouard (E)

Département des sciences biologiques, and Centre de recherche BioMed, Université du Québec à Montréal, Montréal, QC, Canada. edouardels@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH